Advantage Investment Management’s Ionis Pharmaceuticals IONS Stock Holding History

Advantage Investment Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$9K	Hold	150	–	–	0.01%	665
2019 Q2	$10K	Hold	150	–	–	0.01%	659
2019 Q1	$12K	Hold	150	–	–	0.01%	618
2018 Q4	$8K	Hold	150	–	–	0.01%	696
2018 Q3	$8K	Hold	150	–	–	0.01%	756
2018 Q2	$6K	Hold	150	–	–	﹤0.01%	736
2018 Q1	$7K	Hold	150	–	–	﹤0.01%	734
2017 Q4	$8K	Hold	150	–	–	﹤0.01%	733
2017 Q3	$8K	Hold	150	–	–	﹤0.01%	737
2017 Q2	$8K	Hold	150	–	–	﹤0.01%	746
2017 Q1	$6K	Hold	150	–	–	﹤0.01%	780
2016 Q4	$7K	Hold	150	–	–	﹤0.01%	696
2016 Q3	$6K	Hold	150	–	–	﹤0.01%	705
2016 Q2	$3K	Hold	150	–	–	﹤0.01%	752
2016 Q1	$6K	Hold	150	–	–	﹤0.01%	657
2015 Q4	$9K	Hold	150	–	–	﹤0.01%	584
2015 Q3	$6K	Hold	150	–	–	﹤0.01%	628
2015 Q2	$9K	Hold	150	–	–	﹤0.01%	615
2015 Q1	$10K	Hold	150	–	–	0.01%	585
2014 Q4	$9K	Buy	+150	New	+$7.4K	0.01%	539

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Advantage Investment Management's IONS Position: Q3 2019 in Review

Advantage Investment Management held its Ionis Pharmaceuticals (IONS) position steady in Q3 2019 at 150 shares worth $9K. The position accounts for 0.01% of the portfolio, ranked #665.

Advantage Investment Management first reported a position in IONS in Q4 2014 and has held it in 20 quarters since. The position peaked at $12K in Q1 2019. 370 funds tracked by Wall St. Rank hold IONS as of Q3 2019.

Advantage Investment Management held 150 shares of Ionis Pharmaceuticals worth $9K as of Q3 2019.
Advantage Investment Management left its Ionis Pharmaceuticals share count unchanged in Q3 2019.
Ionis Pharmaceuticals made up 0.01% of Advantage Investment Management's portfolio in Q3 2019, its #665 holding.
Advantage Investment Management first reported a position in Ionis Pharmaceuticals in Q4 2014 and has held it in 20 quarters since.
Advantage Investment Management's Ionis Pharmaceuticals position peaked at $12K in Q1 2019.
370 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.